NCT00976222View on ClinicalTrials.gov

Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2015

Conditions
Pigment Epithelial Detachment
Interventions
DRUG

intravitreal injection with ranibizumab

0.5 mg in 0.05 ml, monthly, 12 months

Trial Locations (2)

48149

University Hospital Muenster, Münster

80336

University Hospital Muenchen, München

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University Hospital Muenster

OTHER

NCT00976222 - Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments | Biotech Hunter | Biotech Hunter